Can a female patient diagnosed with pulmonary tuberculosis (PTB) also have a rheumatologic disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can PTB Coexist with Rheumatologic Disease?

Yes, a patient diagnosed with pulmonary tuberculosis (PTB) can absolutely have a concurrent rheumatologic disease, and this association is clinically significant and well-documented. In fact, patients with rheumatic diseases face substantially elevated risks for developing tuberculosis compared to the general population.

The Bidirectional Relationship

The relationship between PTB and rheumatologic conditions works in both directions:

Rheumatic Disease Increases TB Risk

Patients with autoimmune rheumatic diseases have markedly increased susceptibility to tuberculosis 1. The evidence demonstrates:

  • Systemic lupus erythematosus (SLE) patients have a 4.90-fold increased risk of PTB 1
  • Rheumatoid arthritis (RA) patients show a 2.00-fold increased risk of PTB 1
  • Sjögren's syndrome carries a striking 6.11-fold increased risk 1

This heightened vulnerability stems from multiple factors: the underlying immune dysregulation inherent to rheumatic diseases, chronic disease burden that depletes host defenses, and critically, the immunosuppressive medications used to manage these conditions 2, 3.

Immunosuppressive Therapy as a Major Risk Factor

The use of glucocorticoids and disease-modifying antirheumatic drugs (DMARDs) significantly suppresses immune function and creates conditions favorable for TB reactivation 4, 5. This is particularly concerning with:

  • TNF-α antagonists (infliximab, etanercept, adalimumab), which are highly effective for autoimmune conditions but substantially increase TB risk 6
  • Chronic corticosteroid therapy, which is a well-established risk factor for TB development 7, 2
  • Combination immunosuppressive regimens that compound infection risk 8

Clinical Recognition Challenges

Diagnostic Pitfalls

TB in rheumatic disease patients presents with atypical features that can lead to delayed diagnosis or misdiagnosis 3. Key challenges include:

  • Overlapping symptoms: Fever, weight loss, fatigue, and joint symptoms occur in both active rheumatic disease and TB, making differentiation difficult
  • Atypical radiographic presentations: The chest X-ray may not show classic upper lobe cavitary disease 9
  • Immunosuppression masking typical findings: Reduced inflammatory response may result in less prominent radiographic changes 9

Extrapulmonary Manifestations

Rheumatic disease patients face elevated risks not only for PTB but also for extrapulmonary tuberculosis (EPTB) 1:

  • RA patients: 4.67-fold increased EPTB risk
  • Sjögren's syndrome: 5.94-fold increased EPTB risk
  • Progressive systemic sclerosis/polymyositis/dermatomyositis: 8.31-fold increased EPTB risk

This includes rare presentations like Poncet's disease—a reactive, non-destructive arthritis occurring with active TB without direct joint infection 10. This can mimic inflammatory arthritis and lead to diagnostic confusion.

Practical Clinical Approach

When to Suspect Concurrent Disease

Maintain high clinical suspicion for TB in any rheumatic disease patient with:

  • Persistent cough lasting >2-3 weeks 6
  • Constitutional symptoms (fever, night sweats, weight loss, anorexia) 9, 6
  • New or worsening respiratory symptoms despite appropriate rheumatic disease treatment
  • Recent initiation or escalation of immunosuppressive therapy 4, 5
  • Residence in or travel to TB-endemic areas 6

Diagnostic Workup

Do not rely solely on tuberculin skin testing (TST) in immunosuppressed patients 9. The approach should include:

  1. Comprehensive history: TB exposure, prior positive TST, BCG vaccination status, risk factors 9
  2. Chest imaging: CT scan with attention to atypical patterns—any lung zone infiltrates, mediastinal/hilar adenopathy, or even normal radiographs are possible 9
  3. Microbiologic confirmation:
    • Sputum AFB smear and culture (3-5 specimens on different days) 9
    • Molecular testing (GeneXpert MTB/RIF) for rapid diagnosis 11
    • Note: Negative smears do not exclude TB—only 50-80% of PTB cases are smear-positive 9
  4. IGRA testing: Preferred over TST in patients with BCG vaccination history 4
  5. Consider bronchoscopy: For tissue diagnosis when sputum is non-diagnostic 9

Critical Caveat

A negative tuberculin skin test does NOT rule out active tuberculosis in immunosuppressed patients 9. False-negative rates increase with advancing immunosuppression. Even with negative current testing, a history of prior positive TST remains clinically meaningful 9.

Screening Recommendations

All patients with rheumatic diseases should undergo TB screening before initiating biologic DMARDs or other potent immunosuppressants 4, 5, 8. The 2012 ACR guidelines and 2022 EULAR recommendations emphasize:

  • Baseline screening with TST and/or IGRA 4, 5
  • IGRA preferred in BCG-vaccinated individuals 4
  • Chest radiography when clinically indicated, even with negative immunologic tests 4
  • Consider repeat screening in high-risk patients or those switching biologics 5
  • Referral to TB specialists for latent TB treatment before immunosuppression 4

Treatment Considerations

When TB is diagnosed in a rheumatic disease patient, standard first-line anti-TB therapy should be initiated promptly 11, 8. However:

  • Severe adverse drug reactions occur more frequently in rheumatic disease patients (36.1% vs 12.5% in controls) 3
  • Drug-drug interactions between anti-TB medications and DMARDs/immunosuppressants require careful management 8
  • Modification of first-line regimens due to toxicity is more common (19.4% vs 8.3%) 3
  • Despite these challenges, long-term outcomes remain favorable with appropriate management 3

The decision to continue, modify, or temporarily hold immunosuppressive therapy during TB treatment must be individualized based on rheumatic disease activity, TB severity, and drug interactions 8.

References

Research

Increased risk of pulmonary and extra-pulmonary tuberculosis in patients with rheumatic diseases.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2015

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.